On the morning of the 21st, Peking University and Pluo Pharmaceutical Co., Ltd. signed an agreement to jointly build the “Peking University-Prologue Pharmaceutical Joint Laboratory for Nucleic Acid Drugs and Biomantry”. The two sides will carry out industry-university-research collaborative research on the chemistry and biosynthesis of small nucleic acid APIs, promote the deep integration of basic research advantages of universities with the industrialization transformation capabilities of enterprises, and provide technical support for the expansion of Prodrug Pharmaceuticals' CDMO business in the field of nucleic acid drugs and biological manufacturing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.